Compare UPBD & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UPBD | SVRA |
|---|---|---|
| Founded | 1986 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 1996 | 2009 |
| Metric | UPBD | SVRA |
|---|---|---|
| Price | $19.91 | $5.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $32.25 | $7.33 |
| AVG Volume (30 Days) | 862.8K | ★ 1.8M |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | ★ 8.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $4,695,061,000.00 | N/A |
| Revenue This Year | $5.96 | N/A |
| Revenue Next Year | $6.47 | $430.87 |
| P/E Ratio | $32.52 | ★ N/A |
| Revenue Growth | ★ 8.67 | N/A |
| 52 Week Low | $15.82 | $1.98 |
| 52 Week High | $28.03 | $7.01 |
| Indicator | UPBD | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 61.42 | 60.63 |
| Support Level | $17.17 | $4.77 |
| Resistance Level | $20.99 | $6.15 |
| Average True Range (ATR) | 0.86 | 0.28 |
| MACD | 0.17 | 0.07 |
| Stochastic Oscillator | 86.13 | 69.28 |
Upbound Group Inc is an omnichannel platform company committed to elevating financial opportunity for all through inclusive, and technology-driven financial solutions that address the evolving needs and aspirations of consumers. It has four operating segments; The Rent-A-Center Business segment operates lease-to-own stores, the Acima segment offers the lease-to-own transaction to consumers who do not qualify for financing from the traditional retailer, and also offers the lease-to-own transaction through virtual offering solutions, Mexico segment offers lease-to-own stores in Mexico. The The Brigit segment offers various financial health products and tools to help users improve their financial health. The company derives a majority of its revenue from the Acima segment.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).